Jun 14, 2013 Universal H7N9 vaccine generates protective HAI antibodies against unmatched influenza strain in 100% of tested animals; also shows how quickly Inovio can respond to a pandemic threat
|
May 14, 2013 Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man
|
|
|
Apr 18, 2013 Broadly targeted SynCon® H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain
|
Apr 18, 2013 Biotech recognized for VGX-3100, an innovative therapy for pre-cancers and cancers caused by HPV, now in phase II for cervical dysplasia
|
Apr 10, 2013 Inovio to Advance Painless Device to Simultaneously Deliver Multiple Vaccines Using Electroporation Technology
|
Apr 2, 2013 Inovio Plans to Initiate Phase I/IIa Study of its Proprietary, Next Generation HCV Therapeutic Vaccine in 2013
|
|
|
|
|
|
|
|
|
|
|
Feb 11, 2013 Company invites individual and institutional investors to log-on to view presentation
|
Feb 5, 2013 Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference
|
|
|
Jan 9, 2013 Phase I/IIa Trial Follows Preclinical Study Demonstrating for First Time that a Multi-Antigen HCV Vaccine Can Generate Potent T-Cell Response in Liver
|
Jan 7, 2013 Follow-on Agreement Will Lead to Clinical Trials
|
| |
